Webinar: Cancer Neoantigens as Targets for Natural and Therapeutic Anti-Tumor Responses

Dr. Robert Schreiber addresses how mouse and human cancers have been used to identify therapeutically useful tumor neoantigens, how these neoantigens can form the basis for personalized cancer vaccines, and what additional forms of therapy are needed to optimize the therapeutic effects of personalized cancer vaccines.

Webinar: New Checkpoint Molecules That Regulate Anti-Tumor Immunity

Dr. Vijay K. Kuchroo of Harvard Medical School and the Broad Institute describes using RNA and protein expression profiling at single-cell resolution to identify a module of co-inhibitory receptors, including several novel surface receptors.

Webinar: Spatial Characterization of the Lung Tumor Microenvironment in Response to KRAS G12C Inhibition

The first inhibitor targeting KRAS G12C was recently approved for the treatment of locally advanced or metastatic NSCLC. In this webinar, Dr. Febe van Maldegem of The Francis Crick Institute will discuss the group's development of an Imaging Mass Cytometry workflow to phenotypically and spatially characterize the tumor microenvironment in mouse tissues. Using this approach, they have shown how targeted KRAS G12C inhibition leads to a dramatic remodeling of the lung tumor microenvironment.

A Deeper View of Cancer with Single-Cell Multiomics

See how researchers are using our TotalSeq™ reagents to accelerate cancer research by determining mechanisms of regulation of immune checkpoint inhibitors and creating an atlas of human tumors.

Read the blog>

Posters

Our Cancer Immunoediting poster describes the mechanisms by which the immune system responds to cancer and can be broadly split into three phases: elimination, equilibrium, and escape.

During the elimination phase, the immune system surveils and eliminates tumor cells through the production of inflammatory cytokines, recognition of tumor antigens by dendritic cells, or activation of natural killer cells.

Equilibrium describes a phase of cancer persistence in which there is a selection for tumor cells that were not eliminated. Tumor cells are selected through immune cell exhaustion or inhibition, genetic and epigenetic changes, or resistance to immune detection.

Escape occurs when tumors cells have avoided immune detection and are able to grow and expand.

Request a physical copy>